Gland Pharma Limited
Symboli: GLAND.NS
NSE
1688.1
INRMarkkinahinta tänään
42.3302
P/E-suhde
-1.6054
PEG-suhde
278.05B
MRK Cap
- 0.00%
DIV Tuotto
Gland Pharma Limited (GLAND-NS) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 38362 | 32427.2 | 24465 | |||||||
balance-sheet.row.short-term-investments | 0 | 19273 | 29268.9 | 19546.8 | |||||||
balance-sheet.row.net-receivables | 0 | 8715.3 | 12514.7 | 12726.8 | |||||||
balance-sheet.row.inventory | 0 | 19453 | 11856.7 | 12751.7 | |||||||
balance-sheet.row.other-current-assets | 0 | 2477.8 | 1722.3 | 1292.9 | |||||||
balance-sheet.row.total-current-assets | 0 | 69008.1 | 58520.8 | 51236.4 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 17361 | 17269 | 13244.4 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.long-term-investments | 0 | -733.7 | 2000 | -19477.3 | |||||||
balance-sheet.row.tax-assets | 0 | 958.9 | -415.1 | 0 | |||||||
balance-sheet.row.other-non-current-assets | 0 | 1064.4 | 836.1 | 19957.3 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 18767.3 | 19815.4 | 13724.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.account-payables | 0 | 5873.5 | 4628.5 | 4007.3 | |||||||
balance-sheet.row.short-term-debt | 0 | 7.1 | 2.6 | 3 | |||||||
balance-sheet.row.tax-payables | 0 | 9.8 | 179.8 | 286.9 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 37.4 | 44.8 | 47 | |||||||
Deferred Revenue Non Current | 0 | 49.9 | 55.5 | 56.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 924.7 | 552.6 | 63.3 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 896.8 | 939.8 | 803.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 6.3 | 8.1 | 9.3 | |||||||
balance-sheet.row.total-liab | 0 | 8188.1 | 6760 | 5928.4 | |||||||
balance-sheet.row.preferred-stock | 0 | 15.6 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 164.7 | 164.3 | 163.6 | |||||||
balance-sheet.row.retained-earnings | 0 | 60153.9 | 52343.4 | 40226.8 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -15.6 | 114.5 | 240.9 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 19268.6 | 18953.9 | 18401.1 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 0 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 18539.3 | 2000 | 69.5 | |||||||
balance-sheet.row.total-debt | 0 | 44.5 | 47.4 | 50 | |||||||
balance-sheet.row.net-debt | 0 | -19044.4 | -3110.8 | -4868.3 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 10545.8 | 16185.5 | 13348.1 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 1467.4 | 1103 | 987.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -4143.8 | -3254 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 46.2 | 155.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -4179.4 | -3930.8 | -4357.6 | |||||||
cash-flows.row.account-receivables | 0 | 1440 | -4195.7 | -602 | |||||||
cash-flows.row.inventory | 0 | -7596.3 | 895 | -5188.9 | |||||||
cash-flows.row.account-payables | 0 | 1209.8 | 658.5 | 1428.2 | |||||||
cash-flows.row.other-working-capital | 0 | 767.2 | -1288.6 | 5.1 | |||||||
cash-flows.row.other-non-cash-items | 0 | -4194.1 | -1352.4 | -830.4 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.acquisitions-net | 0 | -12705.6 | 6117.2 | 4.3 | |||||||
cash-flows.row.purchases-of-investments | 0 | -4699.8 | -16818.1 | -13575.9 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 17405.4 | 10700.9 | -4.3 | |||||||
cash-flows.row.other-investing-activites | 0 | 14313.1 | -4805 | 623.7 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 12081.9 | -10026.2 | -15240 | |||||||
cash-flows.row.debt-repayment | 0 | -1.1 | -1.4 | -8.9 | |||||||
cash-flows.row.common-stock-issued | 0 | 215 | 385.5 | 12418.1 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -64.7 | -35.2 | -24.6 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 149.2 | 349 | 12384.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 30 | 33.1 | 35.8 | |||||||
cash-flows.row.net-change-in-cash | 0 | 15900.8 | -1736.4 | 3229.7 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 19089 | 3188.2 | 4924.6 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3188.2 | 4924.6 | 1695 | |||||||
cash-flows.row.operating-cash-flow | 0 | 3639.7 | 7907.7 | 6049.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.free-cash-flow | 0 | 1408.5 | 2686.5 | 3761.5 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 36246 | 43841.4 | 34236.4 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 16854.3 | 21092.2 | 14918.7 | |||||||
income-statement-row.row.gross-profit | 0 | 19391.7 | 22749.3 | 19317.6 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.operating-expenses | 0 | 10611.5 | 8745.5 | 7280.4 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 27465.7 | 29837.7 | 22199.2 | |||||||
income-statement-row.row.interest-income | 0 | 1794.2 | 1386.5 | 859.5 | |||||||
income-statement-row.row.interest-expense | 0 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.interest-expense | 0 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1467.4 | 1103 | 987.8 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | 8844.4 | 14000.3 | 12034.5 | |||||||
income-statement-row.row.income-before-tax | 0 | 10545.8 | 16185.5 | 13348.1 | |||||||
income-statement-row.row.income-tax-expense | 0 | 2735.4 | 4068.9 | 3378.5 | |||||||
income-statement-row.row.net-income | 0 | 7810.4 | 12116.6 | 9969.6 |
Usein kysytty kysymys
Mikä on Gland Pharma Limited (GLAND.NS) taseen loppusumma?
Gland Pharma Limited (GLAND.NS) kokonaisvarat ovat 87775350000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on N/A.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.605.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on 35.155.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.134.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on 0.189.
Mikä on Gland Pharma Limited (GLAND.NS) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 7810430000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 44530000.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 10611470000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 0.000.